Key Takeaways
- On-track quarter, but order intake softens: Revenue and profitability are in line with FY25 guidance, yet order intake in technologies and systems weakened as the chemical sector slowdown persisted.
- International business delivers record profitability: Operational excellence and pricing improvements drove the highest-ever profit in the international segment, even as a mix shift toward technology sales pressured gross margins.
- A strategic pivot to non-glasslined is accelerating: Management is actively diversifying revenue away from glasslined equipment, targeting a 50/50 split with non-glasslined, services, and systems, with the mixing business flagged as a faster-growing, higher-margin engine.
- Working capital consumed by a one-two punch: A decline in customer advances and a ~₹50 crores increase in Mavag POC drove a significant working capital hit, now embedded in the base, with liquidation expected in H2.
- What to watch next quarter: Whether the promised large project orders materialize in November and December, the pace of working capital liquidation, and any concrete updates on the MixPro integration and mixing division leadership.
Demand & Order Intake
- Chemical sector slowdown bites: Order intake in technologies and systems was subdued due to general weakness in the chemical sector, while the services business remains on track.
- Agrochemical bottoming out: Management believes agrochemical has likely reached a trough, with raw material prices stabilized and overstocking being consumed, though specialty chemicals continue to perform okay.
- Pharma poised for FY25: Pharma investment is picking up, with Indian companies like Divis, Laurus, and Neuland already expanding capacity; the real play is expected in FY25. Internationally, pharma remains strong in the Americas and Europe, though the overheated mode in Europe is somewhat over.
- October intake strong, pipeline hopeful: October order intake was quite strong, and management expects large projects pushed out by the slowdown to materialize in November and December, making this year "completely sorted."
- Market share gains in a down market: The company believes it has gained glasslined market share in India over the last six months by being more aggressive in capturing orders, with all major project orders coming to GMM Pfaudler. Internationally, the EPIQ program has increased share in Southern and Eastern Europe.
Tarak Patel: "chemical is cyclical. We've always known this obviously we've been in an upcycle for the last maybe five to six years so people didn't realize that there's also a down cycle."
International Business Turnaround
- Record profitability delivered: The international business recorded its highest-ever profitability this quarter, driven by operational excellence and pricing improvements.
- The margin mechanics: Profit margins improved from 7.5% to nearly 15% because orders currently in the P&L were booked when energy and material prices peaked, allowing price increases, while the cost structure has since stabilized. New facilities in Germany, China, and Italy have also ramped up, providing better fixed cost absorption.
- Revenue scale-up from execution, not just demand: The significant revenue improvement from $175 million to $250-$300 million came from operational excellence, improved execution, and pricing improvement, not merely market tailwinds.
- Gross margin dip is mix-driven, not structural: Gross margins in the international business were lower this quarter because the technology business, which consumes more raw material, was higher. Management clarified this is a mix-related issue, not competitive pressure.
- Productivity offsets regional wage inflation: Employee cost increases from regional inflation were countered by increasing prices and improving productivity through operational excellence programs and better operational processes.
Strategic Diversification: Non-Glasslined & Mixing
- The 50/50 ambition: Management's stated goal is to reduce glasslined revenue from 70% to 50% of the total, with the remaining 50% coming from non-glasslined products, services, and systems, to mitigate concentration risk.
- Mixing business as the growth engine: The mixing business is expected to grow at a much faster pace than glasslined over the next few years, with a target to build it into at least a $100 million business, doubling it in a three-to-five-year period.
- Global mixing footprint now complete: With the MixPro acquisition in Canada, the company now has a mixing presence in India, Europe, China, and North/South America. A dedicated mixing division is being set up, with an experienced industry leader joining at the beginning of the next calendar year.
- Mixing margins structurally higher: Management stated that mixing is generally a profitable business and, in most cases, will probably deliver better margins than glasslined, citing a fermentation project where EBITDA margins exceeded 30% while competing against a Chinese company.
- New end-market wins: In India, the mixing business has won orders in lithium processing, biorefining, and gold beneficiation, expanding beyond its traditional chemical and pharmaceutical base.
Tarak Patel: "Our idea is to be in the top five mixing companies in the world. I mean, obviously, it's not going to happen overnight, but I think the progress that we have made so far both with the acquisition and both with the resources that we have added, I think over the next few years, you will see the mixing business really kind of grow at a much faster pace than our glasslined business."
India Standalone: Margin & Growth
- Slow revenue growth in a tough market: Standalone revenue growth slowed to about 4% due to a challenging market in India for the last 6-9 months, especially in chemical and pharmaceutical segments. The company has been more aggressive in the market and focused on increasing exposure in other segments.
- EBITDA margins range-bound: Standalone EBITDA margins are tracking between 14% and 14.5% and are expected to remain in this range for the rest of the year, given the next 6-9 months look "not all that super exciting."
- Raw material tailwind absorbed: Raw material costs have cooled to pre-spike levels, and most high-cost inventory has now been flushed out, with the company now buying inventory at market prices.
- India turnaround expected faster: Management believes India will turn around much faster than the international business because it currently has a smaller backlog and needs to run faster to capture demand.
- Services strategy broadening: The strategic intent is to grow India services from ~9-10% to double digits by servicing other equipment in chemical and pharmaceutical plants, not just GMM Pfaudler's own installed base.
Tarak Patel: "Our future goals, you know, our strategic intent really is to not only stop at servicing our own equipment, but we should also be able to service other equipment as well in a chemical or pharmaceutical plant."
Balance Sheet & Working Capital
- Working capital consumed by two forces: The decline in customer advances, driven by a backlog reduction from March to September and a fall in advances as a percentage of backlog from 19% to 16%, combined with a ~₹50 crores increase in Mavag POC from an Operational Excellence program, drove the working capital consumption.
- Base reset, H2 liquidation expected: The working capital hit has gone into the base as of October 1st, and management expects to liquidate a significant portion in H2 as manufacturing progresses, with initiatives already started and results expected by March 31st.
- Debt reduction on track: The company expects to prepay more long-term debt in H2, targeting total FY24 long-term debt reduction of ~₹140 crores, reflecting lender confidence and its 'AA-' credit rating.
- Non-core asset sales to continue: Management is continuing to identify non-critical, non-core balance sheet items to get leaner.
- Unbilled revenue stable: Unbilled revenue should remain more or less stable with a marginal reduction as the company progresses.
Capital Allocation & Corporate Updates
- DBAG exits, ChrysCapital enters: DBAG Fund VI sold a 13.6% stake; 9.9% was bought by ChrysCapital, with 1% remaining with DBAG that the Patel family has promised to acquire. The transaction, priced at ₹1,700 per share, is expected to close around November 20th, with French approval already received.
- MixPro acquisition fills the Americas gap: The company signed an agreement to purchase a 100% stake in MixPro, a mixing company in Ontario, Canada, for ~$7 million, with the transaction expected to complete by November 30th, giving access to North and South America.
- Board reconstituted: DBAG's nominee directors resigned following the stake sale; the current board has six directors, four of whom are independent.
- Investor Day planned: Management hopes to host an Investor Day by the end of this financial year to update on the long-term vision.
- Future guidance possible: Management indicated it may at some point look to give guidance beyond FY25, engaging with stakeholders to build strategies and identify areas of improvement.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY25 revenue and profitability | In line with FY25 guidance; management is "perfectly on plan" and expects to complete the year as planned | FY25 |
| Long-term debt reduction | Prepay more long-term debt in H2; total FY24 reduction of ~₹140 crores | H2 FY24 |
| Mavag POC liquidation | Liquidate a significant portion as manufacturing progresses; initiatives started, results expected by March 31st | By March 31st |
| MixPro acquisition close | 100% stake purchase for ~$7 million expected to complete | By November 30th |
| DBAG/ChrysCapital transaction close | Remaining 1% DBAG stake to be acquired by Patel family; transaction at ₹1,700 per share | Around November 20th |
| Mixing business revenue target | Build mixing business to at least $100 million, doubling it | Three-to-five-year period |
| Glasslined revenue share target | Reduce glasslined from 70% to 50% of revenue; rest from non-glasslined, services, and systems | Over next two or three years |
| Standalone EBITDA margins | Expected to remain in 14%-14.5% range | Rest of FY24 |
| Investor Day | Host to update on long-term vision | By end of FY24 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Consolidated revenue | ₹937 cr, +20% YoY |
| Consolidated EBITDA | ₹142 cr, ~20% higher than last year |
| Consolidated EBITDA margin | ~15%, improvement driven by international business execution and pricing |
| H1 FY24 revenue | ₹1,850 cr, +22% YoY |
| H1 FY24 EBITDA | ₹274 cr, +27% YoY |
| H1 FY24 EBITDA margin | 14.8% |
| Standalone business revenue growth | ~4% YoY |
| Standalone business EBITDA margin | 14%–14.5% |
| International business profit margin | nearly 15%, up from 7.5% two to three years ago |
| Order backlog | ₹1,705 cr, ~6 months visibility in India, ~7–8 months internationally |
| Order backlog change QoQ | declined ~₹300 cr |
| Order intake, October 2023 | ₹250–270 cr |
| Services share of consolidated revenue | 35%–40% |
| India services share of revenue | 9%–10% |
| Global glasslined market share | 40%–50% |
| Long-term debt reduction in H1 FY24 | ₹77 cr, including ₹29 cr prepayment |
| Expected FY24 long-term debt reduction | ~₹140 cr |
| Consolidated interest rate | 7.5% |
| India interest rate | 8.1% |
| Receivables days | 48 days |
| Inventory reduction, past 6 months | ~₹70 cr |
| Customer advances | ₹270 cr, down from ₹406 cr in March |
| Customer advances as % of backlog | 16%, down from 19% in March |
| Cash generation in H1 FY24 | ₹251 cr |
| POC increase in Mavag, H1 FY24 | ~₹50 cr |
| Mixing business current revenue | $41–42 million (India ~$20M, Mixel ~$15M, MixPro ~$7–8M) |
| Mixing business target revenue | at least $100 million, in three-to-five years |
| Mixing business EBITDA margin | 15%–20% |
| Heavy Engineering margin target | 12%–15% |
| Chemical processing product lines margin profile | 15%–20% |
| India glasslined EBITDA margin | ~16% |
| International glasslined EBITDA margin | ~12% |
| MixPro acquisition consideration | $7 million |
| DBAG stake sale transaction price | ₹1,700 per share |
| Effective tax rate guidance | 27% |